AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Agrees to Financially Support Roswell Park Comprehensive Cancer Center in its Phase 1/2a trial of Ampligen

While the pandemic continues to wreak havoc many global pharmaceutical companies are retooling their operations to help in making everything, which can stop the rapid spread. This includes ventilators, rubber gloves, respirators, and hand sanitizers, among others. Other giants such as AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) have chosen a different path; collaboration to help fast-track the development of possible vaccines.

The immuno-pharma company has agreed to work with Roswell Park Comprehensive Cancer Center, which is pursuing a Phase 1/2a trial of Ampligen and interferon alfa-2b. Cancer patients with COVID-19 are the primary targets of the trial. According to the CEO of AIM ImmunoTech, Thomas K. Equels, the preclinical studies are so promising and encouraging.

‘’… we are encouraged by the potential for an effective early-onset treatment against this new and deadly virus especially for cancer patients, who face significantly increased risk of severe symptoms or death…,’’ Equels commented.

AIM Immunotech Is Playing a Significant Role in This Project 

AIM’s participation and collaboration in this study are very vital in making this project a success. First, the company has made a name in the development of therapeutics for multiple types of cancers. Secondly, it is playing a financial supporter role. This will be accomplished through grants from different quarters.

Roswell Park has always been driven by the need to improve immune-based approaches in the treatment of infectious diseases. Hence, AIM’s involvement in this noble cause is one big milestone for Roswell Park.

The fact that the U.S. Food and Drug Administration has allowed the trial, which will enroll 12-24 patients to proceed, is another support into the vision of Roswell Park.

AIM is also working with Japan’s National Institute of Infectious Diseases 

There are hundreds of promising vaccine candidates being pursued across the world. AIM will also partner with Japan’s National Institute of Infectious Diseases (NIID) through a material transfer and research agreement. Shionogi & Co., Ltd will also be incorporated as a test outlet for AIM’s drug Ampligen.

Shionogi is one of the leading pharmaceutical companies in the world and with foremost experts in the field. The company’s focus is mainly on pain/CNS, infectious diseases, and cancer medicines.